Skip to main content

Boehringer Ingelheim strengthens leading position in biotechnology: Investment of € 70 Million in the high-tech site in Biberach

Pressmeddelande   •   Okt 27, 2005 16:15 CEST

Biberach/Germany, 27 October 2005 - Boehringer Ingelheim invests € 70 million into its biopharmaceutical production plant in Biberach. This new investment is a move to strengthen the company’s leading position in the development and manufacturing of biopharmaceuticals in the long term. With the laying of the foundation stone, the modernization and expansion of the first biotechnological production facility, which was established in 1985, was started. Already in 1992 and 1997, the plant had been modernized and considerably expanded to meet state-of-the-art requirements.

Boehringer Ingelheim’s investment into the future will secure and create jobs at this production site. The Research & Development and Biotechnology site in Biberach offers jobs for approximately 4,000 people – with a total of 1,600 of these employees in the Biopharmaceuticals business.

“The new investment will cover the adaptation to new process technologies, the modernization of the existing plant including process control system as well as the expansion for the purification of drug substance derived from high expression systems for which Boehringer Ingelheim has established its own intellectual property “, emphasized Prof. Dr. Rolf G. Werner, Director Corporate Division Biopharmaceuticals at the headquarters Boehringer Ingelheim GmbH.

The completion of the shell construction with its seven production floors is scheduled for the Spring of 2006. In the new rooms, processing equipment for the purification of protein active substances from processes with high yields will be established. In Autumn 2007 the existing building complex and the expansion will become one unit.

With a biotechnical production capacity of twelve 15,000 liter fermenters in Biberach, Boehringer Ingelheim is one of the largest and leading manufacturers of biopharmaceuticals worldwide. The company provides the entire biotechnical process chain in early development and large-scale commercial manufacturing from cell-line development, production including fermentation and protein chemistry, downstream processing and formulation to filling and finishing in state-of-the-art application systems as well as global registration and marketing of biopharmaceuticals. Boehringer Ingelheim provides contract manufacturing services for leading biotechnology companies, mainly in the U.S., for example Amgen or MedImmune.

Boehringer Ingelheim doubled its capacity at the Biberach site for the development and production of pharmaceutically active substances already in mid-2004, when the company obtained the FDA approval for this new facility. More than € 255 million had been invested in the project, which created more than 400 new jobs in Biberach.

There are four Boehringer Ingelheim sites worldwide for the development, manufacturing or fill and finish of biopharmaceuticals. The largest biotech production site in Biberach concentrates on Cell Culture. The three other production sites are located in Vienna, Austria (focus on Microbial Fermentation Technology), in Bedford, Ohio/USA (focus on aseptic Fill & Finish) and in St. Joseph, Missouri/USA (Veterinary Vaccines).

A total of twelve biopharmaceuticals have until now successfully been brought to international registration through Boehringer Ingelheim, six of them in the past five years.

In 2004, the biopharmaceutical third-party business (development and contract manufacturing) was the strongest growing business segment within the Boehringer Ingelheim group of companies; sales grew by 40 per cent to € 392 million.

Related links:
Picture: Project draft of the modernization of the biotechnological production plant
Boehringer Ingelheim`s Biopharmaceuticals Website

Boehringer Ingelheim GmbH & Co. KG
Heidrun Thoma
55216 Ingelheim
Phone: +49 6132 773966
Fax: +49 6132 773999